Picton Mahoney Asset Management Buys New Stake in Profound Medical Corp. (NASDAQ:PROF)

Picton Mahoney Asset Management bought a new stake in Profound Medical Corp. (NASDAQ:PROFFree Report) in the 4th quarter, Holdings Channel.com reports. The fund bought 250,000 shares of the company’s stock, valued at approximately $1,879,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Profound Medical in the 3rd quarter valued at approximately $612,000. Gagnon Securities LLC increased its holdings in Profound Medical by 12.6% in the 4th quarter. Gagnon Securities LLC now owns 1,652,531 shares of the company’s stock valued at $12,411,000 after purchasing an additional 185,284 shares during the last quarter. Gagnon Advisors LLC boosted its position in Profound Medical by 20.0% in the 4th quarter. Gagnon Advisors LLC now owns 896,671 shares of the company’s stock valued at $6,734,000 after buying an additional 149,445 shares during the period. Truist Financial Corp purchased a new position in Profound Medical in the 4th quarter valued at approximately $376,000. Finally, Ring Mountain Capital LLC purchased a new position in Profound Medical in the 4th quarter valued at approximately $2,087,000. Institutional investors and hedge funds own 47.86% of the company’s stock.

Profound Medical Stock Performance

Shares of PROF stock opened at $6.95 on Friday. The company has a quick ratio of 5.16, a current ratio of 6.12 and a debt-to-equity ratio of 0.11. Profound Medical Corp. has a 52 week low of $5.63 and a 52 week high of $11.42. The stock has a market capitalization of $208.78 million, a PE ratio of -5.19 and a beta of 0.78. The firm has a 50 day moving average of $6.96 and a two-hundred day moving average of $7.50.

Profound Medical (NASDAQ:PROFGet Free Report) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.11. Profound Medical had a negative net margin of 349.41% and a negative return on equity of 85.22%. The company had revenue of $4.18 million during the quarter, compared to analysts’ expectations of $5.92 million. On average, research analysts predict that Profound Medical Corp. will post -1.12 EPS for the current fiscal year.

About Profound Medical

(Free Report)

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.

Read More

Want to see what other hedge funds are holding PROF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Profound Medical Corp. (NASDAQ:PROFFree Report).

Institutional Ownership by Quarter for Profound Medical (NASDAQ:PROF)

Receive News & Ratings for Profound Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medical and related companies with MarketBeat.com's FREE daily email newsletter.